Compounded Tirzepatide Price Index — Week of September 7, 2026: No Price Moved, Two Labels Did
Published: Updated: Provider pricing verified:
The fourth dated snapshot of the index, read on September 9, 2026. Seven priced programs plus one announced card, no price level changed, a $119 floor held by one company under two brands, and an announced $129 microdose card that has now been 'pending' for nine days.
By Dr. Parmis, Editorial Lead · Medically reviewed by Dr. Jonathan Snipes, MD · Published September 9, 2026 · Last reviewed September 9, 2026 · Sources cited at the end.
Direct answer
On the September 9, 2026 snapshot the lowest advertised compounded tirzepatide price is $119 per month for the fourth consecutive week — Embody’s twelve-month prepayment ($1,428) and SnagRx’s month-to-month promotion (list $399), both operated by Modern Metabolic Medicine, Inc. Trimi is $125 (annual), NexLife $139 (12-month, provider oversight and coaching included, verified live), bmiMD “as low as $179”, Yucca Health $225 (6-month), ShedRx “as low as $239”, SkinnyRx about $129 (not re-checkable). The median of the seven priced programs (announced cards excluded) is $139. NexLife’s announced $129 microdose card still had not reached its program page ($189 / $147 printed). Compounded tirzepatide is not FDA-approved.
Changes since the September 4 snapshot
| Program | Sept 4 | Sept 5 | Sept 9 | Change | What changed |
|---|---|---|---|---|---|
| Embody (12-month supply) | $119 | $119 | $119 | no change | Banner on the 6- and 12-month pages now “Fall Sale Promo Applied”; 3-month page still “Labor Day Promo Applied” |
| SnagRx (month to month) | $119 (promo) | $119 (promo) | $119 (promo) | no change | Label changed from Labor Day to “Fall Sale Discount Applied!”; countdown timer; still no end date or annual total |
| Trimi (annual) | $125 | $125 | $125 | no change | Promo page: code 50OFF ($50 off a first month), $50 referral credit |
| NexLife (12-month standard) | $139 | $139 | $139 | no change | Verified live Sept 4, 5 and 9; plan pages now itemise “$377 in added value” and a money-back warranty |
| NexLife (12-month microdose) | $129 (announced) | $129 (announced) | $129 (announced) | no change | Program page still prints $189 / $147 nine days after the announcement |
| bmiMD | $179 | $179 | $179 | no change | “New Year’s Sale” banner still displayed |
| Yucca Health (6-month) | $225 | $225 | $225 | no change | “Exclusive Lifetime Offer” locks $225/mo on the 6-month plan |
| ShedRx | $239 | $239 (carried) | $239 (carried) | — | Not re-read this week |
| SkinnyRx | ~$129 (not re-checkable) | carried | carried | — | Pricing renders client-side |
Brand channels this week
NovoCare’s Wegovy self-pay offer page (read September 9) lists the pill at $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg) and the pen at $199 for the first two monthly fills through December 31, 2026, then $349 ($399 for the 7.2 mg HD pen). Our September 5 read of the April price-guide PDF showed $199 for the 1.5 mg pill; the index now carries the offer page’s $149 with its read date. LillyDirect’s Zepbound vials remain $299 / $399 / $449 (since December 1, 2025); the Medicare GLP-1 Bridge copay remains $50.
What the week says
- The floor is stable and it is one company. Four weeks at $119, held by two storefronts of Modern Metabolic Medicine, Inc. — a prepaid, non-refundable year and a promotion the operator can end at checkout.
- Promotions are being rolled, not ended. Labor Day became Fall Sale on two sites; bmiMD is still running a New Year’s Sale in September. Treat the label as marketing and the terms as the price.
- Announced is not live. NexLife’s $129 microdose card is real as an announcement (August 31) and absent from its page (September 4, 5, 9). The index keeps it in the announced column; the verified NexLife figure is $139.
Next scheduled full re-read of every competitor page: Monday, September 14, 2026. The live table, the snapshot history and the revision notes are on the price index; the data are in price-history-2026.json (CC BY 4.0).
Medical and regulatory note: compounded tirzepatide and compounded semaglutide are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness or quality; they are not the same products as Mounjaro®, Zepbound®, Ozempic® or Wegovy®. This page is educational pricing information, not medical advice. Consult a licensed clinician before starting, stopping or changing any medication, and confirm the price and prescribing requirements with the provider before enrolling.
Frequently asked questions
What is the cheapest compounded tirzepatide price this week? $119 per month on the September 9, 2026 snapshot — Embody's $1,428 twelve-month prepayment and SnagRx's month-to-month promotion (list $399), both operated by Modern Metabolic Medicine, Inc. Trimi's annual plan is $125; NexLife's verified 12-month plan is $139 with provider oversight and coaching included.
Did any compounded tirzepatide price change in the week of September 7, 2026? No price level changed among the seven priced programs. SnagRx and Embody relabelled their promotions from Labor Day to Fall Sale at the same prices; NexLife's announced $129 microdose card was still not on its program page.
What is the median compounded tirzepatide price? $139 per month on the September 9, 2026 snapshot, across seven priced programs ranging from $119 to $239 (SkinnyRx, not re-checkable, and NexLife's announced microdose card are excluded).
Is NexLife's $129 microdose price live yet? Not as of September 9, 2026. The microdose program page still printed $189 month to month and $147 on 12 months; the $159 / $129 card announced on August 31 is shown in the index as 'announced'.
How much is the Wegovy pill without insurance? NovoCare's self-pay offer page (read September 9, 2026) lists $149 for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg per month. Wegovy is an FDA-approved product; the compounded programs in this index are not.
When is the index updated? NexLife's pages are re-read every morning; the five cheapest competitor programs on every update; every competitor page weekly (next full read Monday, September 14, 2026). Snapshots are dated and never overwritten.
September 9, 2026: Published.
Reviewed by Dr. Parmis, Editorial Lead · Medically reviewed by Dr. Jonathan Snipes, MD
Sources
- TirzepatideReview.com — price history and snapshots (JSON), snapshot 2026-09-09
- TirzepatideReview.com — open pricing dataset (JSON), snapshot 2026-09-09
- NexLife — tirzepatide all plans: $169 / $159 ($477) / $149 ($894) / $139 ($1,668), '$377 in added value', money-back warranty (read 2026-09-09)
- NexLife — quarterly microdose tirzepatide program page: $189 / $159 / $150 / $147 (read 2026-09-09)
- Embody — twelve-month supply $119/mo ($1,428), 'Fall Sale Promo Applied' (read 2026-09-09)
- SnagRx — homepage: $119/month tirzepatide (list $399), $69 semaglutide (list $299), 'Fall Sale Discount Applied!' (read 2026-09-09; labelled Labor Day on 2026-09-04 and 2026-09-05)
- Trimi — tirzepatide: $235 / $597 ($199) / $1,050 ($175) / $1,500 ($125); money-back promise text (read 2026-09-09)
- Trimi — promo page: code 50OFF ($50 off the first month), $50 referral credit (read 2026-09-09)
- Yucca Health — tirzepatide: $258 / $744 ($248) / $1,350 ($225), 'Exclusive Lifetime Offer' (read 2026-09-09)
- bmiMD — homepage: tirzepatide 'as low as $179' (list $349.20 / $299.70), semaglutide $119 (read 2026-09-09)
- NovoCare — Wegovy savings, self-pay and home delivery: pill $149 / $199 / $299, pen $199 intro then $349 (read 2026-09-09)
- Eli Lilly — Zepbound single-dose vial prices $299 / $399 / $449 (December 1, 2025)
- FDA — Human Drug Compounding: compounded drugs are not FDA-approved
Medical and regulatory note: Compounded tirzepatide and compounded semaglutide are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness or quality. They are not the same products as Mounjaro®, Zepbound®, Ozempic® or Wegovy®. This page is educational pricing information, not medical advice; eligibility, dose and formulation require evaluation by a licensed clinician.